Good drugs, bad drugs - relationship with the improved performance of the pharmaceutical industry and intensified war against illegal drugs

To suffer and long for relief is a central experience of humanity. But the absence of pain or discomfort or what Pablo Neruda called "the infinite ache" is never enough.

more «

GSK packages enhance the interaction between patient and product: GSK's packaging upgrades run the gamut of products and range from simple to enormously complex

In the last year, GlaxoSmithKline has used packaging to strengthen new and established products, both over-the-counter (consumer) and prescription (trade).

» more

Who can cure the pharmaceuticals? Margaret Cook on how the influence of drugs companies has seeped, through their control of research and even of the official regulator, into the fabric of medical life

"Trying to force a financial camel through the eye of a scientific needle" was the metaphor used to describe the Herculean task of regulating pharmaceutical companies.

more «

Toxic tipping point: once government regulators and pharmaceutical companies knew that mercury in childhood vaccines might be responsible for an epidemic of autism, did they publicize their data and mount a recall? No. They were more concerned with protecting the national vaccine program—and shielding themselves from liability

IN AUGUST OF 2001, Rita Shreffler of Nixa, Missouri, sent her son's baby tooth to a lab. A year earlier, nine-year-old Andy had been diagnosed with Asperger's syndrome, a form of autism.

» more

Health & Care

New book

New book: critical condition—how health care in America became big business & bad medicineThe U.S. spends more on health care than other countries. In 2003, it accounted for 15.3% of the gross domestic product, a greater percentage than Germany.

Fighting the battle

Fighting the battle against health care fraud: CEO vigilance can help ensure better care for allHealth care fraud is a dangerous and expensive crime. The national cost tops $85 billion a year and is a burden borne by all of us--employers.

Battles over Generic

Battles over Generic access will wage on in 2002 - A View from the Top - health care issures bode well for the generic drugs industry - Brief ArticleThe convergence of such weighty issues as national health care costs, global health care access and obligations to a growing elderly population have placed the generic drug industry in the spotlight.

Trends in employer

Trends in employer-provided prescription-drug coverage: prescription-drug costs have been rising faster than the rate of inflation; although coverage remains an integral part of employee health care plans, covered employees share a greater portion of the cost of prescription drugs and are being offered cost-saving incentives more than ever beforePrescription drugs are an integral part of the high-quality health care those living in the United States have come to know. More than 60 percent of Americans fill at least one prescription annually.